These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 21358672)

  • 1. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
    Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
    Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M; Hirai S; Yamada-Okabe H; Hamada K; Tabuchi H; Kobayashi K; Kondo K; Yoshida M; Yamashita A; Kishida T; Nakaigawa N; Nagashima Y; Kubota Y; Yao M; Ohno S
    Oncogene; 2003 May; 22(18):2728-38. PubMed ID: 12743597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
    An J; Rettig MB
    Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
    Turcotte S; Desrosiers RR; Beliveau R
    Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis.
    Schoenfeld AR; Parris T; Eisenberger A; Davidowitz EJ; De Leon M; Talasazan F; Devarajan P; Burk RD
    Oncogene; 2000 Nov; 19(51):5851-7. PubMed ID: 11127815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
    Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma.
    Zeng L; Bai M; Mittal AK; El-Jouni W; Zhou J; Cohen DM; Zhou MI; Cohen HT
    Cancer Res; 2013 Sep; 73(17):5371-80. PubMed ID: 23824745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
    Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL).
    Guo Y; Schoell MC; Freeman RS
    Oncogene; 2009 Apr; 28(16):1864-74. PubMed ID: 19305426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WSB1 promotes tumor metastasis by inducing pVHL degradation.
    Kim JJ; Lee SB; Jang J; Yi SY; Kim SH; Han SA; Lee JM; Tong SY; Vincelette ND; Gao B; Yin P; Evans D; Choi DW; Qin B; Liu T; Zhang H; Deng M; Jen J; Zhang J; Wang L; Lou Z
    Genes Dev; 2015 Nov; 29(21):2244-57. PubMed ID: 26545811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
    Qi H; Ohh M
    Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.